VTRS Overview

Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.

Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Viatris Inc revenue for the last quarter amounts to 3.52B USD, increased 8.07

Viatris Inc. EPS for the last quarter amounts to 0.15 USD, decreased -105.88

Viatris Inc (VTRS) has 30000 emplpoyees as of June 01 2026.

Today VTRS has the market capitalization of 18.94B USD.